# Camp4 Therapeutics Corp: financial statements, quarterly

CAMP · Nasdaq · CIK 1736730 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/camp.md) · [Financials](/companies/camp/financials.md) · [Filings](/companies/camp/filings.md) · [Insiders](/companies/camp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/camp/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001410578-24-002045.md) | [0.0 d](/filings/0001736730-25-000022.md) | [0.0](/filings/0001736730-25-000039.md) | [0.0](/filings/0001736730-25-000070.md) | [0.0](/filings/0001736730-25-000094.md) | [0.7 d](/filings/0001736730-26-000016.md) | [0.9](/filings/0001736730-25-000039.md) | [1.5](/filings/0001736730-25-000070.md) | [0.8](/filings/0001736730-25-000094.md) | [0.3 d](/filings/0001736730-26-000016.md) | [1.3](/filings/0001628280-26-032146.md) | [1.8](/filings/0001628280-26-056760.md) |
| Research and development | $m | [9.8](/filings/0001410578-24-002045.md) | [10.7 d](/filings/0001736730-25-000022.md) | [9.7](/filings/0001736730-25-000039.md) | [9.4](/filings/0001736730-25-000070.md) | [9.7](/filings/0001736730-25-000094.md) | [10.0 d](/filings/0001736730-26-000016.md) | [10.1](/filings/0001628280-26-032146.md) | [10.3](/filings/0001628280-26-056760.md) | [9.4](/filings/0001736730-25-000094.md) | [8.4 d](/filings/0001736730-26-000016.md) | [10.2](/filings/0001628280-26-032146.md) | [10.8](/filings/0001628280-26-056760.md) |
| Operating income | $m | [(12.3)](/filings/0001410578-24-002045.md) | [(13.5) d](/filings/0001736730-25-000022.md) | [(12.9)](/filings/0001736730-25-000039.md) | [(12.7)](/filings/0001736730-25-000070.md) | [(13.5)](/filings/0001736730-25-000094.md) | [(14.0) d](/filings/0001736730-26-000016.md) | [(13.1)](/filings/0001628280-26-032146.md) | [(13.0)](/filings/0001628280-26-056760.md) | [(13.7)](/filings/0001736730-25-000094.md) | [(12.8) d](/filings/0001736730-26-000016.md) | [(13.1)](/filings/0001628280-26-032146.md) | [(13.4)](/filings/0001628280-26-056760.md) |
| Income tax | $m | [0.0](/filings/0001410578-24-002045.md) | [0.0 d](/filings/0001736730-25-000022.md) | [0.0](/filings/0001736730-25-000039.md) | [0.0](/filings/0001736730-25-000070.md) | [0.0](/filings/0001736730-25-000094.md) | [0.0 d](/filings/0001736730-26-000016.md) | [0.0](/filings/0001628280-26-032146.md) | [0.0](/filings/0001628280-26-056760.md) | [0.0](/filings/0001736730-25-000094.md) | [0.0 d](/filings/0001736730-26-000016.md) | [0.0](/filings/0001628280-26-032146.md) | [0.0](/filings/0001628280-26-056760.md) |
| Net income | $m | [(11.7)](/filings/0001410578-24-002045.md) | [(13.0) d](/filings/0001736730-25-000022.md) | [(12.5)](/filings/0001736730-25-000094.md) | [(12.6)](/filings/0001736730-25-000094.md) | [(13.5)](/filings/0001736730-25-000094.md) | [(13.3) d](/filings/0001736730-26-000016.md) | [(12.4)](/filings/0001628280-26-056760.md) | [(12.6)](/filings/0001628280-26-056760.md) | [(15.1)](/filings/0001736730-25-000094.md) | [(40.3) d](/filings/0001736730-26-000016.md) | [(18.3)](/filings/0001628280-26-056760.md) | [(33.5)](/filings/0001628280-26-056760.md) |
| Diluted EPS | $ per share | [(29.21)](/filings/0001410578-24-002045.md) | not reported | [(26.57)](/filings/0001736730-25-000039.md) | [(26.00)](/filings/0001736730-25-000070.md) | [(24.19)](/filings/0001736730-25-000094.md) | not reported | [(0.62)](/filings/0001628280-26-032146.md) | [(0.62)](/filings/0001628280-26-056760.md) | [(0.55)](/filings/0001736730-25-000094.md) | not reported | [(0.32)](/filings/0001628280-26-032146.md) | [(0.58)](/filings/0001628280-26-056760.md) |
| Basic EPS | $ per share | [(29.21)](/filings/0001410578-24-002045.md) | not reported | [(26.57)](/filings/0001736730-25-000039.md) | [(26.00)](/filings/0001736730-25-000070.md) | [(24.19)](/filings/0001736730-25-000094.md) | not reported | [(0.62)](/filings/0001628280-26-032146.md) | [(0.62)](/filings/0001628280-26-056760.md) | [(0.55)](/filings/0001736730-25-000094.md) | not reported | [(0.32)](/filings/0001628280-26-032146.md) | [(0.58)](/filings/0001628280-26-056760.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [50.5](/filings/0001410578-24-002045.md) | [38.4](/filings/0001736730-25-000022.md) | not reported | not reported | [2.5](/filings/0001410578-24-002045.md) | [64.0](/filings/0001736730-26-000016.md) | [49.3](/filings/0001736730-25-000039.md) | [39.1](/filings/0001736730-25-000070.md) | [75.3](/filings/0001736730-25-000094.md) | [110](/filings/0001628280-26-056760.md) | [99.2](/filings/0001628280-26-032146.md) | [86.4](/filings/0001628280-26-056760.md) |
| Current assets | $m | not reported | [40.0](/filings/0001736730-25-000022.md) | not reported | not reported | [5.5](/filings/0001410578-24-002045.md) | [66.4](/filings/0001736730-26-000016.md) | [51.7](/filings/0001736730-25-000039.md) | [41.1](/filings/0001736730-25-000070.md) | [77.7](/filings/0001736730-25-000094.md) | [114](/filings/0001628280-26-056760.md) | [102](/filings/0001628280-26-032146.md) | [90.0](/filings/0001628280-26-056760.md) |
| Total assets | $m | not reported | [54.9](/filings/0001736730-25-000022.md) | not reported | not reported | [21.4](/filings/0001410578-24-002045.md) | [78.3](/filings/0001736730-26-000016.md) | [62.8](/filings/0001736730-25-000039.md) | [51.3](/filings/0001736730-25-000070.md) | [86.4](/filings/0001736730-25-000094.md) | [118](/filings/0001628280-26-056760.md) | [105](/filings/0001628280-26-032146.md) | [93.4](/filings/0001628280-26-056760.md) |
| Current liabilities | $m | not reported | [7.8](/filings/0001736730-25-000022.md) | not reported | not reported | [11.8](/filings/0001410578-24-002045.md) | [9.6](/filings/0001736730-26-000016.md) | [6.4](/filings/0001736730-25-000039.md) | [7.3](/filings/0001736730-25-000070.md) | [7.9](/filings/0001736730-25-000094.md) | [15.5](/filings/0001628280-26-056760.md) | [16.6](/filings/0001628280-26-032146.md) | [19.1](/filings/0001628280-26-056760.md) |
| Total liabilities | $m | not reported | [16.5](/filings/0001736730-25-000022.md) | not reported | not reported | [18.2](/filings/0001410578-24-002045.md) | [15.2](/filings/0001736730-26-000016.md) | [11.2](/filings/0001736730-25-000039.md) | [11.3](/filings/0001736730-25-000070.md) | [27.7](/filings/0001736730-25-000094.md) | [70.1](/filings/0001628280-26-056760.md) | [74.6](/filings/0001628280-26-032146.md) | [94.1](/filings/0001628280-26-056760.md) |
| Shareholders' equity | $m | [(112)](/filings/0001410578-24-002045.md) | [(124)](/filings/0001736730-26-000016.md) | [(135)](/filings/0001736730-25-000094.md) | [(147)](/filings/0001736730-25-000094.md) | [(159)](/filings/0001736730-25-000094.md) | [63.1](/filings/0001628280-26-056760.md) | [51.6](/filings/0001628280-26-056760.md) | [40.0](/filings/0001628280-26-056760.md) | [58.7](/filings/0001736730-25-000094.md) | [47.7](/filings/0001628280-26-056760.md) | [30.9](/filings/0001628280-26-056760.md) | [(0.7)](/filings/0001628280-26-056760.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.8) d](/filings/0001736730-25-000022.md) | [(11.1)](/filings/0001736730-25-000039.md) | [(13.4) d](/filings/0001736730-25-000070.md) | [(9.7) d](/filings/0001736730-25-000094.md) | [(11.3) d](/filings/0001736730-26-000016.md) | [(14.3)](/filings/0001628280-26-032146.md) | [(10.3) d](/filings/0001628280-26-056760.md) | [(11.2) d](/filings/0001736730-25-000094.md) | [6.3 d](/filings/0001736730-26-000016.md) | [(11.0)](/filings/0001628280-26-032146.md) | [(12.7) d](/filings/0001628280-26-056760.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001736730-25-000022.md) | [0.0](/filings/0001736730-25-000039.md) | [0.2 d](/filings/0001736730-25-000070.md) | [0.0 d](/filings/0001736730-25-000094.md) | [0.3 d](/filings/0001736730-26-000016.md) | [0.3](/filings/0001628280-26-032146.md) | [0.0 d](/filings/0001628280-26-056760.md) | [0.0 d](/filings/0001736730-25-000094.md) | [0.0 d](/filings/0001736730-26-000016.md) | [0.0](/filings/0001628280-26-032146.md) | [0.1 d](/filings/0001628280-26-056760.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.4](/filings/0001410578-24-002045.md) | [0.5](/filings/0001736730-25-000039.md) | [0.5](/filings/0001736730-25-000070.md) | [0.6](/filings/0001736730-25-000094.md) | [20.2](/filings/0001628280-26-032146.md) | [20.2](/filings/0001628280-26-056760.md) | [27.3](/filings/0001736730-25-000094.md) | [57.9](/filings/0001628280-26-032146.md) | [57.9](/filings/0001628280-26-056760.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,753,200 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001628280-26-056760.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.